Anti-Cancer Combination Drug Derived from Chinese Herbs

Overview

This invention is an effective combination pharmaceutical that consists of active ingredients of Traditional Chinese Medicine (TCM). The efficacy of this anti-cancer drug is comparable with, or even higher than that of 5-Fluorouracil (5FU), which is one of the chemotherapy drugs for treating cancer nowadays.

  • Anti-Cancer Combination Drug Derived from Chinese Herbs 0
  • Anti-Cancer Combination Drug Derived from Chinese Herbs 1
  • Anti-Cancer Combination Drug Derived from Chinese Herbs 2
Commercialisation opportunities
technology licensing agreement
Problem addressed

Drug resistance may be developed after prolonged usage of single-target anticancer drug. Combinational drug therapy is one of the most promising strategies in modern anticancer research. Using different combinations of anticancer drugs may exhibit synergistic effects and reduce the drug resistance. This multi-pronged effect could increase therapeutic efficacy.

Innovation
  • This combinational drug consists of Halofuginone (HF) and Artemisinin (ATS), which are compounds extracted from Chinese herbs.
  • In the preliminary studies, the combination of HF and ATS showed inhibitory effects on different cancer cells, including colon, breast, liver, gastric and skin cancer. Its efficacy is comparable with, or even higher than that of current anti-cancer drug 5FU.
  • After conducting the animal study, it is demonstrated that the drug could provide significant therapeutic effect on colon cancer without severe adverse effects through our observation.
Key impact
  • Patients can benefit from a new and safe anti-cancer drug with higher efficacy and lower toxicity. These potential combinational drugs in TCM might provide alternative options for cancer treatment.
Application
  • This pharmaceutical combination can be used in treating colon, breast, liver, gastric and skin cancer.
Hong Kong Baptist University (HKBU)

Aspiring to be a leading, research-led, liberal arts University in Asia, Hong Kong Baptist University is committed to conducting world-leading investigations that extends the frontiers of knowledge, tackles global challenges and benefits the community at home and abroad. 

Pursuing research excellence is one of the priorities of the University’s Institutional Strategic Plan 2018-2028. The University keeps enhancing its capacity and strength to produce world-class research with an aim to bring significant impact to the society. 

Enquiry